NasdaqGM:XOMA

Stock Analysis Report

Executive Summary

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific.

Snowflake

Fundamentals

Mediocre balance sheet with questionable track record.

Share Price & News

How has XOMA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XOMA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.7%

XOMA

1.9%

US Biotechs

0.5%

US Market


1 Year Return

78.5%

XOMA

8.1%

US Biotechs

12.8%

US Market

Return vs Industry: XOMA exceeded the US Biotechs industry which returned 8.1% over the past year.

Return vs Market: XOMA exceeded the US Market which returned 12.8% over the past year.


Shareholder returns

XOMAIndustryMarket
7 Day11.7%1.9%0.5%
30 Day32.5%11.6%4.3%
90 Day41.9%7.9%8.0%
1 Year78.5%78.5%9.1%8.1%15.3%12.8%
3 Year223.2%223.2%14.0%10.5%48.3%38.7%
5 Year-70.8%-70.8%5.2%0.3%62.6%44.5%

Price Volatility Vs. Market

How volatile is XOMA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is XOMA undervalued compared to its fair value and its price relative to the market?

8.04x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: XOMA ($23.69) is trading above our estimate of fair value ($0.36)

Significantly Below Fair Value: XOMA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: XOMA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XOMA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XOMA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XOMA is overvalued based on its PB Ratio (8x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is XOMA forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

66.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XOMA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XOMA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XOMA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XOMA's revenue (13.5% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: XOMA's revenue (13.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XOMA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has XOMA performed over the past 5 years?

45.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XOMA has high quality earnings.

Growing Profit Margin: XOMA's current net profit margins (-8.4%) are higher than last year (-125.1%).


Past Earnings Growth Analysis

Earnings Trend: XOMA is unprofitable, but has reduced losses over the past 5 years at a rate of 45.1% per year.

Accelerating Growth: Unable to compare XOMA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XOMA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (69.3%).


Return on Equity

High ROE: XOMA has a negative Return on Equity (-2.61%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is XOMA's financial position?


Financial Position Analysis

Short Term Liabilities: XOMA's short term assets ($44.0M) exceeds its short term liabilities ($10.1M)

Long Term Liabilities: XOMA's short term assets (44.0M) do not cover its long term liabilities (50.2M)


Debt to Equity History and Analysis

Debt Level: XOMA's debt to equity ratio (126.7%) is considered high

Reducing Debt: XOMA had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: XOMA has a low level of unsold assets or inventory.

Debt Coverage by Assets: XOMA's debt is covered by short term assets (assets are 1.3x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XOMA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XOMA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is XOMA's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate XOMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XOMA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XOMA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XOMA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XOMA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of XOMA's salary, the management and board of directors tenure and is there insider trading?

2.9yrs

Average management tenure


CEO

Jim Neal (63yo)

2.9yrs

Tenure

US$1,323,455

Compensation

Mr. James R. Neal, also known as Jim, serves as Director at Leading BioSciences Inc since October 30, 2018. He has been the Chief Executive Officer at XOMA Corporation since December 21, 2016 and served as ...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD1.32M) is about average for companies of similar size in the US market ($USD1.17M).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.9yrs

Average Tenure

45yo

Average Age

Experienced Management: XOMA's management team is considered experienced (2.9 years average tenure).


Board Age and Tenure

4.9yrs

Average Tenure

63yo

Average Age

Experienced Board: XOMA's board of directors are considered experienced (4.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$408,22815 May 19
BVF Partners LP
EntityCompany
Shares27,913
Max PriceUS$14.74
SellUS$1,91214 May 19
W. Van Ness
EntityIndividual
Role
Chairman of the Board
Chairman of the Board & Lead Independent Director
Shares130
Max PriceUS$14.71
BuyUS$354,79320 Dec 18
BVF Partners LP
EntityCompany
Shares25,000
Max PriceUS$14.19
BuyUS$527,24213 Dec 18
BVF Partners LP
EntityCompany
Shares36,463
Max PriceUS$14.75
BuyUS$897,44811 Dec 18
BVF Partners LP
EntityCompany
Shares61,023
Max PriceUS$14.80
BuyUS$146,13905 Dec 18
BVF Partners LP
EntityCompany
Shares9,800
Max PriceUS$14.99
BuyUS$448,48429 Nov 18
BVF Partners LP
EntityCompany
Shares29,700
Max PriceUS$15.24
BuyUS$1,023,65821 Nov 18
BVF Partners LP
EntityCompany
Shares72,253
Max PriceUS$15.00
BuyUS$431,34819 Nov 18
BVF Partners LP
EntityCompany
Shares31,990
Max PriceUS$13.82

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Management Team

  • Jim Neal (63yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$1.32m
  • Danny Hart (43yo)

    VP & General Counsel

    • Tenure: 1.8yrs
  • Tom Burns (45yo)

    Senior VP of Finance & CFO

    • Tenure: 4.6yrs
    • Compensation: US$1.00m

Board Members

  • Jack Wyszomierski (63yo)

    Independent Director

    • Tenure: 9.3yrs
    • Compensation: US$167.01k
  • Joe Limber (66yo)

    Independent Director

    • Tenure: 6.9yrs
    • Compensation: US$160.01k
  • Denny Van Ness (76yo)

    Chairman of the Board & Lead Independent Director

    • Tenure: 8.3yrs
    • Compensation: US$201.01k
  • Jim Neal (63yo)

    CEO & Director

    • Tenure: 2.9yrs
    • Compensation: US$1.32m
  • Matthew Perry (46yo)

    Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$146.01k
  • Barbara Kosacz (60yo)

    Independent Director

    • Tenure: 0.8yrs

Company Information

XOMA Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: XOMA Corporation
  • Ticker: XOMA
  • Exchange: NasdaqGM
  • Founded: 1981
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$207.341m
  • Shares outstanding: 8.75m
  • Website: https://www.xoma.com

Number of Employees


Location

  • XOMA Corporation
  • 2200 Powell Street
  • Suite 310
  • Emeryville
  • California
  • 94608
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XOMANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 1986
X0M1DB (Deutsche Boerse AG)YesCommon StockDEEURJun 1986

Biography

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/12 23:41
End of Day Share Price2019/11/12 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.